Format

Send to

Choose Destination
Br J Pharmacol. 2013 Oct;170(4):693-5. doi: 10.1111/bph.12339.

Evolving pharmacology of orphan GPCRs: IUPHAR Commentary.

Author information

1
Clinical Pharmacology Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.

Abstract

The award of the 2012 Nobel Prize in Chemistry to Robert Lefkowitz and Brian Kobilka for their work on the structure and function of GPCRs, spanning a period of more than 20 years from the cloning of the human β2 -adrenoceptor to determining the crystal structure of the same protein, has earned both researchers a much deserved place in the pantheon of major scientific discoveries. GPCRs comprise one of the largest families of proteins, controlling many major physiological processes and have been a major focus of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) since its inception in 1987. We report here recent efforts by the British Pharmacological Society and NC-IUPHAR to define the endogenous ligands of 'orphan' GPCRs and to place authoritative and accessible information about these crucial therapeutic targets online.

KEYWORDS:

chemerin receptor; chemokine receptors; free fatty acid receptors; hydroxycarboxylic acid receptors; lysophosphatidic acid receptors; oxoglutarate receptor; succinate receptor

PMID:
23957221
PMCID:
PMC3799586
DOI:
10.1111/bph.12339
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center